Tiziana Life Sciences Ltd
TLSA1.540USD
+0.020+1.32%
收盘 12/22, 16:00（美东）报价延迟15分钟
182.99M总市值
亏损市盈率 TTM
关于 Tiziana Life Sciences Ltd 公司
Tiziana Life Sciences Ltd. is a United Kingdom-based clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The Company’s clinical pipeline includes drug assets for secondary progressive multiple sclerosis, Alzheimer’s, and ALS. Its lead immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer’s and other CNS indications. Its Anti-IL-6R mAb (TZLS-501), a fully human mAb, binds to both membrane-bound and soluble forms of IL-6R, an inflammatory cytokine driving chronic inflammation associated with autoimmune and cancer, reducing circulating levels of the IL-6 cytokine. Its oncology product candidate, Milciclib, is a combination therapy for the treatment of refractory solid tumors (being cancers which are non-responsive or become resistant to treatment), especially non-small cell lung cancer (NSCLC).
Tiziana Life Sciences Ltd简介
公司代码TLSA
公司名称Tiziana Life Sciences Ltd
上市日期Nov 20, 2018
CEOElrifi (Ivor)
员工数量8
证券类型Ordinary Share
年结日Nov 20
公司地址3rd Floor, 11-12 St. James's Square
城市LONDON
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United Kingdom
邮编SW1Y 4LB
电话442074952379
网址https://www.tizianalifesciences.com/
公司代码TLSA
上市日期Nov 20, 2018
CEOElrifi (Ivor)
Tiziana Life Sciences Ltd公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Willy Jules Simon
Mr. Willy Jules Simon
Non-Executive Independent Director
Non-Executive Independent Director
8.25K
--
Mr. John P. Brancaccio, CPA
Mr. John P. Brancaccio, CPA
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Gabriele Marco Antonio Cerrone
Mr. Gabriele Marco Antonio Cerrone
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Mr. Ivor Elrifi
Mr. Ivor Elrifi
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Ms. Keeren Shah
Ms. Keeren Shah
Chief Financial Officer, Chief Operating Officer
Chief Financial Officer, Chief Operating Officer
--
--
Dr. William A. Clementi, Pharm.D.
Dr. William A. Clementi, Pharm.D.
Chief Development Officer
Chief Development Officer
--
--
名称
名称/职务
职务
持股
持股变动
Mr. Willy Jules Simon
Mr. Willy Jules Simon
Non-Executive Independent Director
Non-Executive Independent Director
8.25K
--
Mr. John P. Brancaccio, CPA
Mr. John P. Brancaccio, CPA
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Gabriele Marco Antonio Cerrone
Mr. Gabriele Marco Antonio Cerrone
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Mr. Ivor Elrifi
Mr. Ivor Elrifi
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Ms. Keeren Shah
Ms. Keeren Shah
Chief Financial Officer, Chief Operating Officer
Chief Financial Officer, Chief Operating Officer
--
--
Dr. William A. Clementi, Pharm.D.
Dr. William A. Clementi, Pharm.D.
Chief Development Officer
Chief Development Officer
--
--
收入明细
由于公司未披露，未能获取相关数据
由于公司未披露，未能获取相关数据
业务
地区
由于公司未披露，未能获取相关数据
股东统计
更新时间: 12月4日 周四
更新时间: 12月4日 周四
持股股东
股东类型
持股股东
持股股东
占比
Cerrone (Gabriele M)
35.38%
Monica Fonda (Natalia Laura)
5.73%
Chernett (Jorey)
5.45%
Dauntless Investment Group, LLC
2.30%
Marshall Wace LLP
0.23%
其他
50.92%
持股股东
持股股东
占比
Cerrone (Gabriele M)
35.38%
Monica Fonda (Natalia Laura)
5.73%
Chernett (Jorey)
5.45%
Dauntless Investment Group, LLC
2.30%
Marshall Wace LLP
0.23%
其他
50.92%
股东类型
持股股东
占比
Individual Investor
46.56%
Investment Advisor
2.69%
Investment Advisor/Hedge Fund
0.43%
Hedge Fund
0.23%
Research Firm
0.06%
其他
50.02%
机构持股
更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
68
4.64M
3.91%
+430.94K
2025Q2
68
51.10M
45.84%
+9.72M
2025Q1
69
45.10M
40.46%
+3.34M
2024Q4
64
40.33M
36.45%
-5.07M
2024Q3
58
41.30M
37.43%
-3.04M
2024Q2
51
40.27M
36.45%
-4.04M
2024Q1
48
40.16M
36.35%
-4.27M
2023Q4
52
45.25M
44.24%
+1.19M
2023Q3
58
45.24M
44.24%
+1.10M
2023Q2
54
45.32M
44.32%
+1.19M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Cerrone (Gabriele M)
42.04M
35.38%
+2.70M
+6.85%
Mar 31, 2025
Chernett (Jorey)
5.95M
5.01%
+5.95M
--
Jun 11, 2025
Dauntless Investment Group, LLC
3.42M
2.88%
+1.68M
+96.52%
Jun 30, 2025
Marshall Wace LLP
24.37K
0.02%
+24.37K
--
Jun 30, 2025
Zhang Financial LLC
89.76K
0.08%
-6.50K
-6.75%
Jun 30, 2025
Kovitz Investment Group Partners, LLC
79.36K
0.07%
--
--
Jun 30, 2025
Geode Capital Management, L.L.C.
78.20K
0.07%
+319.00
+0.41%
Jun 30, 2025
HSBC Global Asset Management (UK) Limited
105.36K
0.09%
--
--
Jun 30, 2025
查看更多
持股ETF
更新时间: 12月6日 周六
更新时间: 12月6日 周六
机构名称
占比
Fidelity Nasdaq Composite Index ETF
0%
Fidelity Nasdaq Composite Index ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
Oct 20, 2021
Merger
2→1
Oct 20, 2021
Merger
2→1
Oct 20, 2021
Merger
2→1
Oct 20, 2021
Merger
2→1
Jul 16, 2020
Split
1→2.5
公告日期
类型
比率
Oct 20, 2021
Merger
2→1
Oct 20, 2021
Merger
2→1
Oct 20, 2021
Merger
2→1
Oct 20, 2021
Merger
2→1
Jul 16, 2020
Split
1→2.5
常见问题
Tiziana Life Sciences Ltd的前五大股东是谁？
Tiziana Life Sciences Ltd 的前五大股东如下：
Cerrone (Gabriele M)持有股份：42.04M，占总股份比例：35.38%。
Chernett (Jorey)持有股份：5.95M，占总股份比例：5.01%。
Dauntless Investment Group, LLC持有股份：3.42M，占总股份比例：2.88%。
Marshall Wace LLP持有股份：24.37K，占总股份比例：0.02%。
Zhang Financial LLC持有股份：89.76K，占总股份比例：0.08%。
Cerrone (Gabriele M)持有股份：42.04M，占总股份比例：35.38%。
Chernett (Jorey)持有股份：5.95M，占总股份比例：5.01%。
Dauntless Investment Group, LLC持有股份：3.42M，占总股份比例：2.88%。
Marshall Wace LLP持有股份：24.37K，占总股份比例：0.02%。
Zhang Financial LLC持有股份：89.76K，占总股份比例：0.08%。
Tiziana Life Sciences Ltd的前三大股东类型是什么？
Tiziana Life Sciences Ltd 的前三大股东类型分别是：
Cerrone (Gabriele M)
Monica Fonda (Natalia Laura)
Chernett (Jorey)
Cerrone (Gabriele M)
Monica Fonda (Natalia Laura)
Chernett (Jorey)
有多少机构持有Tiziana Life Sciences Ltd(TLSA)的股份？
截至2025Q3，共有68家机构持有Tiziana Life Sciences Ltd的股份，合计持有的股份价值约为4.64M，占公司总股份的3.91%。与2025Q2相比，机构持股有所增加，增幅为-41.94%。
哪个业务部门对Tiziana Life Sciences Ltd的收入贡献最大？
在--，--业务部门对Tiziana Life Sciences Ltd的收入贡献最大，创收--，占总收入的--%。
